◀ Back to EGFR

EGFR — KRAS

Pathways - manually collected, often from reviews:

• KEGG Melanoma: EGFR/FGFR1/IGF1R/MET/PDGFRA/PDGFRB → HRAS/KRAS/NRAS (protein-protein, activation)
• NCI Pathway Database Internalization of ErbB1: RAS family/GDP complex (HRAS_KRAS_HRAS_KRAS_NRAS) → EGFR/EGFR/EGF/EGF/GRB2/SOS1 complex (EGFR-EGF-GRB2-SOS1) (modification, collaborate)
  Haugh et al., J Biol Chem 1999, Pennock et al., Mol Cell Biol 2003, Wiley et al., J Biol Chem 1991, Di Guglielmo et al., EMBO J 1994, Herbst et al., J Biol Chem 1994
  Evidence: assay
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF/GRB2/SOS1 complex (EGFR-EGF-GRB2-SOS1) → RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS) (modification, activates)
  Haugh et al., J Biol Chem 1999, Pennock et al., Mol Cell Biol 2003, Wiley et al., J Biol Chem 1991, Di Guglielmo et al., EMBO J 1994, Herbst et al., J Biol Chem 1994
  Evidence: assay
• NCI Pathway Database Internalization of ErbB1: RAS family/GDP complex (HRAS_KRAS_HRAS_KRAS_NRAS) → EGFR/EGFR/EGF/EGF/p46 SHC/GRB2/SOS1 complex (EGFR-EGF-SHC1-GRB2-SOS1) (modification, collaborate)
  Haugh et al., J Biol Chem 1999
  Evidence: assay
• NCI Pathway Database Internalization of ErbB1: EGFR/EGFR/EGF/EGF/p46 SHC/GRB2/SOS1 complex (EGFR-EGF-SHC1-GRB2-SOS1) → RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS) (modification, activates)
  Haugh et al., J Biol Chem 1999
  Evidence: assay
• NCI Pathway Database Internalization of ErbB1: RAS family/GDP complex (HRAS_KRAS_HRAS_KRAS_NRAS) → EGFR/EGFR/EGF/EGF/p52 SHC/GRB2/SOS1 complex (EGFR-EGF-SHC1-GRB2-SOS1) (modification, collaborate)
  Haugh et al., J Biol Chem 1999
  Evidence: assay
• Reactome Reaction: EGFR → KRAS (reaction) Paez et al., Science 2004, Sordella et al., Science 2004, Shimamura et al., Cancer Res 2005, Janes et al., Oncogene 1994, Chardin et al., Science 1993, Xie et al., J Biol Chem 1995

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• STRING interaction: EGFR — KRAS (interaction, mapped from kegg_pathways)
• STRING interaction: KRAS — EGFR (interaction, mapped from kegg_pathways)

Text-mined interactions from Literome

Toulany et al., Radiother Oncol 2005 : Additionally, Ras mutated cells were transfected with K-Ras-siRNA to investigate, how downregulation of mutated K-Ras affects secretion of EGFR-ligands , stimulation of EGFR signaling and modulation of radiation response
Ida et al., Exp Anim 2010 (Choline Deficiency...) : Furthermore, expression of epidermal growth factor receptor (EGFR) and its ligands ; serine protease inhibitor Kazal type 3 ( Spink3 ) and transforming growth factor alpha ( TGF alpha ) and activation of K-Ras ( GTP-Ras formation ), which are frequently observed in human PDA, were indeed observed in parallel with TCs formation
Yokota et al., Anticancer Agents Med Chem 2012 (Colorectal Neoplasms) : KRAS and BRAF mutations lead to the constitutive activation of EGFR signaling through the oncogenic Ras/Raf/Mek/Erk pathway
Perera et al., Cancer Cell 2012 : In this issue of Cancer Cell, Ardito and colleagues and Navas and colleagues demonstrate that ADM- and KRAS-driven pancreatic cancer require EGFR signaling, revealing a mechanism for developmental reprogramming that primes tumorigenesis
Ardito et al., Cancer Cell 2012 (Carcinoma, Pancreatic Ductal...) : Here, we show that oncogenic KRAS upregulates endogenous EGFR expression and activation, the latter being dependent on the EGFR ligand sheddase, ADAM17
Kato et al., Eur J Cancer 1998 (Endometrial Neoplasms) : An inhibitor of the EGFR tyrosine kinase activity could prevent soft agar colony formation of Ishikawa cells, but not HHUA or mutant K-ras ( 12V ) -transfected Ishikawa cells
Luo et al., Int J Oncol 1999 (Astrocytoma) : Stable expression of activated Ki-Ras does not constitutively activate the mitogen activated protein kinase pathway but attenuates epidermal growth factor receptor activation in human astrocytoma cells